Literature DB >> 28583911

First Tissue-Agnostic Drug Approval Issued.

.   

Abstract

The PD-1 inhibitor pembrolizumab received accelerated approval for adult and pediatric patients with solid tumors that are mismatch repair-deficient or microsatellite instability-high. This is the first time the FDA has greenlighted a drug based not on tumor type, but on a common biomarker. ©2017 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28583911     DOI： 10.1158/2159-8290.CD-NB2017-078

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  18 in total

Review 1.  Trial watch: Immune checkpoint blockers for cancer therapy.

Authors:  Claire Vanpouille-Box; Claire Lhuillier; Lucillia Bezu; Fernando Aranda; Takahiro Yamazaki; Oliver Kepp; Jitka Fucikova; Radek Spisek; Sandra Demaria; Silvia C Formenti; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-31       Impact factor: 8.110

Review 2.  Vaccines for immunoprevention of DNA mismatch repair deficient cancers.

Authors:  Alejandro Hernandez-Sanchez; Mark Grossman; Kevin Yeung; Shizuko S Sei; Steven Lipkin; Matthias Kloor
Journal:  J Immunother Cancer       Date:  2022-06       Impact factor: 12.469

Review 3.  Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors.

Authors:  Denis L Jardim; Débora de Melo Gagliato; Francis J Giles; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2017-12-06       Impact factor: 12.531

4.  A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response.

Authors:  Hao-Dong Li; Changzheng Lu; He Zhang; Qing Hu; Junqiu Zhang; Ileana C Cuevas; Subhransu S Sahoo; Mitzi Aguilar; Elizabeth G Maurais; Shanrong Zhang; Xiaojing Wang; Esra A Akbay; Guo-Min Li; Bo Li; Prasad Koduru; Peter Ly; Yang-Xin Fu; Diego H Castrillon
Journal:  JCI Insight       Date:  2020-07-23

Review 5.  Challenging Standard-of-Care Paradigms in the Precision Oncology Era.

Authors:  Vivek Subbiah; Razelle Kurzrock
Journal:  Trends Cancer       Date:  2018-01-12

Review 6.  American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment.

Authors:  David C Shonka; Alan Ho; Ashish V Chintakuntlawar; Jessica L Geiger; Jong C Park; Nagashree Seetharamu; Sina Jasim; Amr H Abdelhamid Ahmed; Keith C Bible; Marcia S Brose; Maria E Cabanillas; Kirsten Dabekaussen; Louise Davies; Dora Dias-Santagata; James A Fagin; William C Faquin; Ronald A Ghossein; Raj K Gopal; Akira Miyauchi; Yuri E Nikiforov; Matthew D Ringel; Bruce Robinson; Mabel M Ryder; Eric J Sherman; Peter M Sadow; Jennifer J Shin; Brendan C Stack; R Michael Tuttle; Lori J Wirth; Mark E Zafereo; Gregory W Randolph
Journal:  Head Neck       Date:  2022-03-11       Impact factor: 3.821

Review 7.  Colorectal Cancers: An Update on Their Molecular Pathology.

Authors:  Kentaro Inamura
Journal:  Cancers (Basel)       Date:  2018-01-20       Impact factor: 6.639

Review 8.  PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?

Authors:  Zijun Y Xu-Monette; Mingzhi Zhang; Jianyong Li; Ken H Young
Journal:  Front Immunol       Date:  2017-12-04       Impact factor: 7.561

9.  Applying Precision Medicine to Ovarian Cancer: Proof-of-Principle for a "Molecular Second Look".

Authors:  Melissa Schwartz; Olga Camacho-Vanegas; Ashley M Wood; Matthew Dashkoff; Courtney Whitelock; Timothy T Harkins; Carmel J Cohen; Ann Marie Beddoe; Peter Dottino; John A Martignetti
Journal:  Int J Gynecol Cancer       Date:  2018-03       Impact factor: 3.437

Review 10.  PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.

Authors:  Zijun Y Xu-Monette; Jianfeng Zhou; Ken H Young
Journal:  Blood       Date:  2017-11-08       Impact factor: 25.476
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.